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ABSTRACT 
Orofacial clefts are relatively common birth defects with an estimated incidence of 1 in 
700 live births that carry a significant public health burden.  The causal factors of the development 
of orofacial clefts are complex; monogenic, multifactorial, non-syndromic and syndromic forms 
are all described in the literature.  In almost all cases, genetics are thought to play a role in the 
etiology.  In this study, we used an international cohort of 2,141 orofacial cleft patients and their 
families to find individuals with microdeletions, utilizing genome wide SNP chips for genetic 
analyses.  We identified 94 individuals with deletions greater than 750 kb and compared them to 
registries with detailed phenotypic features and medical and family histories.  We divided the 
cohort into distinct groupings: (1) individuals with a highly–penetrant orofacial cleft-associated 
deletion syndrome, (2) individuals with a lower-penetrant orofacial cleft microdeletion, (3) 
individuals with a large deletion encompassing likely contributory genes, and (4) individuals with 
a deletion of unknown significance.  This cohort helps to support previous literature describing 
patients with orofacial clefts and microdeletions, along with presenting rarer associations, 
including an individual with a 12q21.1 deletion and cardiofaciocutaneous-like phenotype, an 
individual with a 7q36.3 deletion within the SHH regulator region with an absent nasal bone and 
cartilage, and an individual with a 3p26.3 deletion with a family history of polydactyly and 
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intellectual disability.  With our cohort, we help to define the range of associated features in 
individuals with microdeletions and orofacial clefts.   
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1.0  INTRODUCTION 
Orofacial clefts are relatively common birth defects with an estimated incidence of 1 in 700 live 
births.1  The impact of clefts is significant:  cost of treatment averages $200,000 across the lifespan, and 
can affect feeding, speech, hearing, dentition, and mental health in affected individuals.2  The causal factors 
of the development of orofacial clefts are complex; monogenic, multifactorial, and syndromic forms are all 
described in the literature.  Monogenic inheritance is seen in conditions such as Stickler syndrome and Van 
der Woude syndrome, and come with health concerns other than orofacial clefts such as learning disabilities 
and vision loss.3  Non-syndromic orofacial clefts are generally seen at a higher frequency, with 
approximately 70% of individuals with cleft lip and palate, and 50% of individuals with cleft palate only, 
considered to be non-syndromic.4  Even in these cases, genetics are thought to play a role in the development 
of clefts.  Concordance between monozygotic twins has been reported as high as 40-60%, and is about 5% 
for dizygotic twins, showing that non-syndromic cleft lip and palate are quite heritable, with an 
environmental influence playing a part in the presentation as well.5  However, despite the discovery of 
many genes associated with the development of clefts, there is still a gap in knowledge in terms of 
unexplained clefting presentations.6 
Much research has been done to better understand the genetic etiology of orofacial clefting, 
including linkage association studies, candidate gene studies, and genome-wide association studies.2,3,7  
While previous studies have provided a wealth of new information, there has been recent investigation into 
the effects of copy number variants on the development of orofacial clefts.  The study of microdeletions 
has been particularly fruitful in other areas of medicine, such as the discovery of a causative gene for 
CHARGE association.8  Traditionally, copy number variants have been detected in patients with syndromic 
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orofacial clefts, such as those with DiGeorge syndrome.  However, recent research has looked at copy 
number variants in candidate genes and smaller family studies in individuals with non-syndromic clefts, 
and found associations between clefts and certain deletions in affected individuals.1,6,8 
To address these gaps in knowledge concerning microdeletions as potential causes of orofacial 
clefts, this study aims to: 
 Identify microdeletions in a cohort of cases and families with orofacial clefts   
 Characterize and review reported phenotypic features in individuals identified with 
microdeletions.  This group will include 94 individuals from multiple countries with a 
microdeletion who have a cleft lip and/or palate, or have a close family member with the 
condition.  
 For microdeletions with no previous connection to orofacial clefts, explore possible role of 
deleted genes in craniofacial development. 
The results of this study will provide information on syndromic and non-syndromic causes of 
orofacial clefting within an ethnically and geographically diverse group. This study will hopefully present 
a collection of data on microdeletions found in individuals with orofacial clefts, and serve as a foundation 
for a variety of other research projects on the molecular basis of cleft lip and palate. After more clinical 
research has been pursued, this information could be used so that individuals with orofacial clefts may be 
screened for these deletions to help predict an individual’s medical prognosis and outcome. 
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2.0  LITERATURE REVIEW  
2.1 OVERVIEW AND EPIDEMIOLOGY OF OROFACIAL CLEFTS 
Orofacial clefts are some of the most common congenital malformations worldwide.  
Orofacial clefting refers to a group of related malformations, primarily affecting the upper lip and 
palate.  The three most common types of orofacial clefts fall into three categories: cleft lip, cleft 
palate, and cleft lip with cleft palate.  Traditionally, cleft lip and cleft lip and palate have been 
combined as one disorder: cleft lip with or without cleft palate (CL/P).9 The international 
prevalence of cleft lip with or without cleft palate is approximately 9.92 per 10,000 births.10 
Worldwide, cases of cleft palate only have been found to have a birth prevalence of 6.39 per 10,000 
births, and cleft lip a prevalence of 3.28 per 10,000 births.11  Orofacial clefts also vary among 
ethnic populations. In the United States, Caucasian populations have the highest recorded 
prevalence of orofacial clefts (1.8 per 1000 births), with individuals of Asian and Hispanic descent 
following closely (1.04 per 1000 births).  African Americans consistently have the lowest 
prevalence of cleft lip and palate in comparison to other racial and ethnic populations (0.67-0.61 
per 1000 births).12  Outside of the US, orofacial clefting tends to be more common in Eastern Asia, 
India, and South America, whereas clefting is less common in Africa and Southern Europe.13  
There is also a difference of prevalence in the sexes, with cleft lip only and cleft lip and palate 
more common in males (1.23:1 and 1.56:1 respectively) and cleft palate only more common in 
females (1.77:1).14 
The high prevalence of orofacial clefts is significant because of the substantial burden these 
malformations have on affected individuals and their families as well as the health care system.  
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Cleft lip and palate increases an individual’s mortality risk, with a standardized mortality ratio of 
1.4 for males and 1.8 for females.15  Management of cleft lip and palate patients requires a team 
of specialists including dentists, radiologists, surgeons, geneticists, speech therapists, feeding 
specialists, and otolaryngologists to provide standard of care.  Surgeries are quite common in these 
patients, and they often consist of multiple oral reconstruction procedures.  Treatment and 
management of clefts is not a luxury that merely corrects cosmetic differences.16 Surgical repair 
of orofacial clefts is required because infants suffer from feeding difficulties that result in low 
weights and sometimes requiring specialized feeding appliances or tools.  As children age, an 
orofacial cleft can also negatively affect speech ability.  Difficulties relating to the palate can lead 
to problems with the middle ear, resulting in an excess of otitis media and even hearing loss.17  On 
average, the average annual cost of medical care of children with an orofacial cleft was $13,405 
more than those without an orofacial cleft in the United States.  Children with a cleft and another 
major defect had costs that were 25 times higher than an unaffected infant.  Lifetime costs for 
medical treatment have been reported to be over $100,000.18 
Medical care of orofacial clefts is not limited to infants or childhood due to additional 
comorbidities. International cleft lip and palate registries show that 29% of affected individuals 
had an additional defect, and could be considered syndromic.  These most commonly included 
polydactyly, limb abnormalities, and cardiac defects.19  Even individuals with apparently isolated 
orofacial clefts have other medical complications, which may not be visible.  For example, 
individuals with isolated orofacial clefts have been found to have abnormal brain structure and 
development in comparison to those without clefts.20  Long term, affected individuals and their 
unaffected family members have an increased risk for cancer, particularly breast cancer, more so 
than the unaffected population.321 
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Having an orofacial cleft has been shown to have a significant psychosocial effect from 
early life throughout adulthood.  Although overall functioning tends to be adequate,22 many 
children and adolescents have reported that they are teased more than their peers at school, an 
experience that often negatively effects an individual psychosocially.  Most of the bullying was 
due to the child’s facial or speech differences.  Many also have noted an unhappiness with an 
aspect of their face related to their orofacial cleft.23  Parents of children with cleft lip and palate 
also reported that their children tended to have more anxiety and depression than their unaffected 
peers, along with more behavioral problems.24 
Orofacial development is complex, as are the factors that contribute to orofacial clefts, 
which include genetic and environmental exposures.4  The negative impact of smoking during 
pregnancy has been widely documented, and orofacial clefting is one outcome that has been 
recorded.  Women who smoked during their pregnancy or were exposed to cigarette smoke (such 
as when living with a smoker) were found to be at an increased risk for isolated cleft lip and 
palate.25   Maternal alcohol use has been looked at for possible connections between cleft lip and 
palate due to the range of other congenital problems that can occur, such as fetal alcohol syndrome.  
Results have been mixed, ranging from conclusions stating that even low levels of alcohol 
consumption can lead to an increased risk for orofacial clefts, to others reporting that there is no 
significant link between the proposed exposure and outcome.262728  Similarly, there is mixed 
evidence that maternal nutritional supplements reduce the risk of orofacial clefts.  Some studies 
suggest that supplementation of folic acid, a compound that has been linked to the fusion of palate 
shelves, can help significantly reduce the risk of orofacial clefts, among other malformations, up 
to 50%.29  Similar results are found when B12 and zinc are supplemented as well.30  This has been 
supported by lower rates of cleft lip and palate in children of women who took a prenatal vitamin.31  
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Maternal health has also been suggested to play a role in orofacial cleft risk.  For example, women 
with diabetes are more likely to have children with a congenital anomaly, including cleft lip and 
palate.32  Multiple studies have supported a correlation between maternal obesity and an increased 
risk to have a child with an orofacial cleft.33,34  Finally, men older than 40 are 58% more likely to 
father children with a cleft lip or palate than their younger (20-39 year-old) male peers.35 
2.2 EMBRYOLOGY OF THE DEVELOPMENT OF THE LIP AND PALATE 
The development of the face is a relatively long, complex, and multi-stepped process.  For 
the face to grow properly, five facial primeval parts must fuse to together.  These include the 
midline frontonasal prominence, two maxillary prominences, and two mandibular prominences.36  
These five structures can be seen around the 4th week of development, and are formed from cranial 
neural crest cells, which in themselves originate from the ectodermal cells of the neural tube.37  
Through multiple stages, including growth and migration, the frontonasal prominences divide in 
to two nasal processes: the medial and the lateral.  From the 6th and 7th week of growth, the nasal 
processes along with both maxillary processes merge together to form the beginnings of the 
primary palate and upper lip.  This is a sensitive time in the development of the face, and errors 
can lead to orofacial clefts in the fetus.38  In a similar series of events, beginning in the 7th week, 
the maxillary prominences begin to form the palate shelves, which in turn becomes the rest of the 
adult hard and soft palate.  During the period, the palatal shelves grow vertically along the tongue.39  
After, the shelves of the palate fuse and elevate to a horizontal position above the tongue.  This 
sets the stage for the differentiation of muscle and bone, creating the soft and hard palates.  As this 
occurs, the palates fuse with the nasal septum, effectively separating the oral and nasal cavities.40  
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2.3 PHENOTYPIC SPECTRUM AND CLASSIFICATION OF OROFACIAL CLEFTS 
There are three general orofacial subgroups that are typically used: cleft lip only (CL), cleft 
lip and palate (CLP) and cleft palate only (CP).  Traditionally, cleft lip and cleft lip and palate have 
been lumped together in the cleft lip with or without cleft palate subgroup (CL/P).  This is because 
development of a severe cleft lip in a fetus can lead to a cleft in the hard or secondary palate.  
However, based on data describing the severity, gender, consanguinity, genetics, and other factors 
that increase the likelihood of CP versus CLP, there is more data supporting the idea of separating 
the two subgroups.4142 
Orofacial clefts vary widely among individuals in severity.  Clefts of the lip can occur 
unilaterally or bilaterally.  Among unilateral clefts, although both are prevalent, left-sided orofacial 
clefts are more common than right-sided.43  Historically, laterality was one of the only descriptors 
used for orofacial clefts.  However, clefts also vary in completeness (i.e., how severely the structure 
is affected).  The LAHSHAL coding system was invented to help easily describe orofacial clefts 
and their severity by noting the anatomy that the cleft has affected.  The acronym addresses clefts 
that affect the lip (L), the alveolus(A), hard (H), and soft (S) palates, as you look at the affected 
individual.  Thus, the left side of the acronym describes the right side of the face, and the right side 
of the acronym the left side of the face.36 More recent literature has shown that in addition to the 
type of cleft present (CP, CLP, and CL), there are also subclinical features that may contribute to 
the entire clinical picture.  These features include submucosal cleft palates, bifid uvulas, and 
microform clefts (a notch composed of a fibrous tissue across the lip).4445 These phenotypes can 
be found in individuals previously thought to be purely unaffected, and further research will 
hopefully help to predict risks for typically affected children.44  Much attention has been given to 
subepithelial defects of the orbicularis oris muscle (OOM defects) and their link to orofacial clefts. 
 8 
OOM defects have been detected in previously described unaffected relatives of patients with 
orofacial clefts at a higher frequency than in control populations.4544  This has led some researchers 
to believe that this feature may be a mild form of orofacial cleft.  Dental anomalies are also 
commonly seen in affected individuals and their relatives.  In one study focusing on unaffected 
parents of children with orofacial clefts, 51% had one or more dental anomalies.  Defects of this 
nature that have been noted include microdontia, tooth displacement, congenital absence of teeth, 
supernumerary teeth, and enamel defects.4647  In unilaterally affected individuals, agenesis of the 
lateral incisor on the side unaffected by clefting is the most common dental anomaly, and may 
potentially be a sign of a reduced penetrance bilateral cleft lip and palate.48  Differences in overall 
face shape between unaffected relatives and control populations have been recorded in the 
literature by using 3-D image capturing to provide a closer look at the details of the face.  These 
changes found in parents of children with orofacial clefting include a flat profile, excess 
intraorbital  and nasal cavity widths, and increased lower and reduced upper facial heights.4950  
Finally, data has been found tying a pattern of lower lip “whorls” and facial clefts.  These unique 
prints resemble the lower lip pits found in the Mendelian orofacial cleft disorder known as Van 
der Woude syndrome, and are found in non-syndromic cases of cleft lip and palate as well as their 
family members.51,52 
2.4 SYNDROMIC CLEFTS 
Although most CL/P cases are isolated, approximately 30% of individuals have other 
congenital defects in addition to an orofacial cleft.19  Patients with multiple anomalies may be 
considered syndromic.  For example, aneuploidy conditions can affect multiple organ systems, and 
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orofacial development is no exception. Almost 20% of all patients with trisomy 13 have cleft lip, 
and more than 4% of patients with trisomy 18.53  Women with Turner syndrome have also been 
reported to have orofacial abnormalities, particularly cleft palate.54,55  Currently, over 500 distinct 
genetic syndromes, including single gene Mendelian disorders, have listed cleft lip and or palate 
among their described features.56 Much progress has been made in determining the genetic 
causation of these syndromes, helping researchers to glean insight into the molecular pathways of 
cleft lip and palate. 
Over 200 mutations in the interferon regulatory factor 6 (IRF6) gene located on 1q32.2 
have been linked to orofacial development and two different syndromic orofacial clefting 
syndromes: Van der Woude syndrome and popliteal pterygium syndrome.575859  As mentioned 
previously, Van der Woude syndrome is a mendelian orofacial clefting disorder.  Although only 
affecting 1 in 35,000 individuals, it accounts for approximately 2% of all orofacial clefts in 
humans.60  An autosomal dominant condition, Van der Woude syndrome (VWS) can present with 
lower lip fistulae, or lip pits, hypodontia, and CL, CP, or CLP.61  Although VWS is highly 
penetrant at about 97%, the features present in affected individuals vary, with lip pits being the 
most common phenotypic characteristic described.62 Popliteal pterygium syndrome (PPS) is the 
second syndromic orofacial clefting disorder associated with IRF6.  It is quite rare, occurring in 1 
in every 300,000 live births.  Like VWS, PPS symptoms include lower lip fistulae and CL, CP, or 
CLP.  Additional phenotypic features are frequently found in PPS patients, such as abnormal 
genitalia, webbing of the skin from the ischial tuberosities (also known as the “sit bones”) to the 
heels, syndactyly of fingers and toes, and dermatological abnormalities of the skin around the nails 
of the hands and feet.63 
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Collagen plays an important role in the development of the palatal shelves, so 
unsurprisingly mutations in collagen producing genes can lead to syndromic orofacial clefts.64  
Stickler syndrome is a highly penetrant autosomal dominant condition affecting 1 in 7,500 live 
births with 90% of patients with myopia, 60% with retinal detachment, 70% with hearing loss, 
90% with joint problems including hypermobility and early onset arthritis, and 84% with 
craniofacial anomalies including cleft palate and midface retrusion.65  Approximately 85% of 
causative pathogenic mutations for Stickler syndrome are found in the COL2A1 gene and about 
10% in the COL11A1 and COL11A2 genes. 66 
2.5 NON-SYNDROMIC CLEFTS 
The majority (approximately 70%) of cleft lip and palate patients present with no additional 
features and have a non-syndromic form of clefting.  Despite a complex array of potential causes, 
there is substantial evidence supporting a genetic etiology for non-syndromic orofacial clefts.676869  
Relative recurrence risk for a CL/P in a first degree relative is 32, indicating a strong genetic 
component to non-syndromic orofacial clefts.70  Twin studies have also provided evidence for a 
significant genetic component; dizygotic twins have a lower concordance rate of 1-5% in 
comparison to that of monozygotic twins with 35-60% concordance rate.4471 
 Multiple approaches have been used to identify genetic risk factors for orofacial clefts.  
Linkage studies, which look at segregation of alleles through families, have produced mixed 
results.  Although many different research studies have found loci thought to contribute to orofacial 
development, few have been successfully replicated.67  One significant locus found via a meta-
analysis of 388 multiplex families is 9q21, which encompasses the suspected causative FOXE1 
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gene.72  The association between this region and cleft lip and palate has been replicated in several 
further candidate gene studies.73,74  Additional linkage findings within this study include loci 2q32-
35 and 16q24. 
Studies of candidate genes like those of FOXE1 have added to the genetic orofacial cleft 
literature.  In a 2004 study, point mutations were found in FOXE1, along with GLI2, MSX2, SKI, 
SATB2 and SPRY2 in a single individual with non-syndromic cleft lip and palate, and in none of 
the 186 controls sequenced.  These results lead researchers to believe that the candidate genes 
listed have a cumulative effect.75 Candidate gene MSX1 was previously found in mice with cleft 
palate.76 Follow up human genetic studies have found that MSX1 mutations can be identified in 
approximately 2% of non-syndromic orofacial clefting.77  Candidate gene selection can be 
performed by choosing syndrome-causing genes associated with clefting.  IRF6, the causative gene 
for Van der Woude syndrome, is also known to be associated with non-syndromic orofacial 
clefts.42  TP63, associated with ectrodactyly-ectodermal dysplasia, and MID1, a causative gene for 
X-linked Opitz G/BBB syndrome, have been linked to non-syndromic clefting as well.78 
Historically, genome wide association studies (GWAS) have been the most successful 
approach for identifying genetic risk factors for orofacial clefts.  A 2010 GWAS with 401 
individuals with non-syndromic cleft lip/palate and 1323 controls showed associations between 
clefting and the loci 17q22 and 10q25.3.79  A separate GWAS that was performed within the same 
year confirmed the significance of IRF6, and also noted links between loci MAFB, ABCA4, and 
8q24.80  Two years later, new susceptibility regions were discovered, including 1p36, 2p21, 
3p11.1, 8q21.3, 13q31.1, and 15q22.81  Most recently, in 2016, 19q13 and 2p24 were new loci 
reaching genome-wide significance in relation to orofacial clefting, in addition to confirming 
associations in 1p36, 1p22, 1q32, 8q24, and 17p13.82  However, despite these successes, GWAS-
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identified loci only account for up to 25% of the heritability of orofacial clefts, indicating that the 
remaining genetic risk could reside in other types of variation such as rare mutations or copy-
number/structural variants.82 
2.6 MICRODELETIONS 
Up to 6% of malformations (including orofacial clefts) are caused by a chromosomal 
abnormality.83  As mentioned previously, aneuploidies like trisomy 13 and monosomy X 
contribute to this figure.  Smaller losses within the chromosomes can also lead to malformations 
like cleft lip or palate.  These microdeletions are commonly associated with syndromic clefting, 
and diagnostic testing like microarray is a useful clinical tool to identify such microdeletions, and 
to take precautionary care for other associated symptoms, such as surveillance for other described 
affected organs of the body. 
22q11.2 deletion syndrome, also known as DiGeorge or Velocardiofacial syndrome, is the 
most well-known microdeletion clefting syndrome.  The gene TBX1 is thought to be responsible 
for most of the features associated with this microdeletion, which include cleft palate, 
developmental delay, intellectual disability, heart defects, autoimmune disorders, hearing loss, 
kidney abnormalities, and psychiatric problems.8485  In children with cleft palate, microarray 
testing to rule out a 22q11.2 deletion is standard of care.86 Other microdeletion syndromes with 
cleft lip and/or palate include 1p36 deletion syndrome,87 Wolf-Hirschhorn syndrome (4p 
deletion),88 and Smith-Magenis syndrome (17p11.2 deletion).89 
Recently, microdeletions are being found in non-syndromic clefting.  Microarray testing 
has revealed new candidate genes for cleft lip and/or palate in individuals with isolated orofacial 
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clefts.  A 2008 study discovered that chromosomal regions 6q25.1-25.2 and 10q26.11-26.13 were 
deleted in patients with cleft lip.  Genes ESR1 and FGFR2, located within those areas, are currently 
suspected to play a role in the clefting seen in these patients.8  Shi et. al (2007) took a similar 
approach, but used genome-wide association studies to search for microdeletions within non-
syndromic orofacial cleft patients.  This data revealed deletions in CYP1B1, FGF10, SP8, SUMO1 
and TFAP2A in their cohort.  Genes such as CYP1B1 play a role in metabolizing toxins, and may 
provide a link between smoking and orofacial clefts if that ability is reduced by a deletion.  
TFAP2A is a gene that is associated with facial development.6  Another study looking at de novo 
microdeletions in individuals with non-syndromic orofacial clefts identified a deletion in the 
7p14.1 region, which has been previously described as causing malformations of the face.90  One 
microdeletion study took a different approach, and looked at inherited deletions in non-syndromic 
clefting participants.  This study revealed two significant deleted regions on chromosomes 7 and 
8: 7q34 and 8q24.91  Further research into the possible significance of the genes involved in rare 
or common microdeletions could help enhance our understanding of the etiology of non-syndromic 
clefting. 
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3.0  MANUSCRIPT  
3.1 BACKGROUND 
Orofacial clefts (OFCs) are common birth defects with an estimated incidence of 1 in 700 
live births.1  All three categories of orofacial clefts, cleft lip (CL), cleft palate (CP), and cleft lip 
with cleft palate (CLP), are linked with many environmental and genetic factors, and can present 
with a variety of other structural anomalies (syndromic) or can be isolated (non-syndromic).3  
Approximately 50% of CP cases and 30% of CL or CLP cases occur as part of syndromes.44  In 
the past, genome wide association studies have been successful at identifying genetic risk factors 
for non-syndromic OFCs.  These studies discovered new loci for non-syndromic OFCs (e.g., 19q13 
and 1p22) as well as identified associations between non-syndromic OFCs and genes typically 
associated with OFC syndromes (e.g., IRF6, GRHL3, and TP63). 79,81,82,92  Despite this success, 
genome wide association studies identified only 25% of heritability of non-syndromic OFCs.82  
The remaining heritability may be accounted for by rare variants, gene-gene or gene-environment 
interactions, or by structural variants.69 
Chromosomal abnormalities, including microdeletions, cause up to 6% of malformations.83  
These small losses in chromosome material can lead to cleft lip and palate when the genetic 
material missing includes genes or regulatory elements that contribute to craniofacial 
development.  Historically, chromosomal aberrations have been detected using many different 
methods.  Large abnormalities such as translocations or aneuploidies can be detected using a 
karyotype, including significantly sized deletions of at least 4-6 Mb.93  This can help determine 
the etiology for a number of patients with cleft, such as those with Turner syndrome.55  
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Fluorescence in situ hybridization (FISH) can pick up known smaller duplications or deletions, 
like those in DiGeorge syndrome or Wolf-Hirschhorn syndrome, but due to its use of a probe, 
FISH is limited to detecting specific, targeted regions within a chromosome, and may miss other 
relevant aberrations within the genome.9486   To detect unknown copy number variants, array 
comparative genome hybridization (CGH) is used, which can pick up chromosomal losses or gains 
within the genome by comparing the sample to a control.95  De novo and rare inherited 
microdeletions have been tied to non-syndromic OFCs, such as in the ESR1 and FGFR2 genes, 
and have been identified in affected individuals using this method in a study performed by 
Oesagawa et al..891   
More recently, SNP arrays have been utilized in clinical and research settings to detect 
copy number variants.  Although SNP arrays are limited by SNP distribution and are not as high 
density compared to CGH testing, they have been used successfully in detection of microdeletions, 
particularly for those with non-syndromic OFCs.9695  In 2009, Shi et al. conducted a study using 
GWAS and SNP array to detect microdeletions in a clefting cohort, revealing deletions in 
candidate genes such as CYP1B1, FGF10, SP8, SUMO1 and TFAP2A.6  Younkin et al. similarly 
used SNP array in individuals with de novo deletions and non-syndromic CL/P, and found a 
deletion along 7p14.1 more commonly observed in cleft trios.90  To follow up, in 2015 Younkin 
and his colleagues conducted the study with inherited deletions within non-syndromic clefting 
individuals, and detected deletions within the MGAM, ADAM3A, and ADAM5 genes.91  In 2016, 
Fu et al. looked at the exome rather than the genome within multiplex OFC families, and utilized 
SNP array to detect microdeletions.  With the use of this technology, 88 hemizygous potentially 
causative deletions were detected from 56 families.97 
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Our international study aims to further understand the role of microdeletions as part of the 
genetic architecture of OFCs.  Using a genome wide SNP array, we have detected 94 
microdeletions larger than 0.75 Mb and have divided them into distinct groups based on 
phenotype, family history, deletion size, and deletion characterization, effectively adding to the 
literature of microdeletions in an OFC cohort. 
3.2 METHODS 
3.2.1 Study Sample 
 Our international cohort was recruited from 18 sites in 13 countries within North America, 
South America, Asia, Europe, and Africa as previously described.82  Recruitment and data 
collection were done at orofacial cleft treatment centers in respective sites as part of ongoing 
studies by the University of Pittsburgh Center for Craniofacial and Dental Genetics and the 
University of Iowa.  Institutional Review Board approval was obtained for each site; informed 
consent was obtained for all participants, including consent for large genomic studies with data 
sharing.  The full cohort of 11,727 samples were comprised of individual OFC cases, their 
unaffected family members, and unrelated controls. 
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3.2.2 Genotyping 
Samples were genotyped for 580,000 single nucleotide polymorphisms (SNPs) on the 
Illumina Human Core+Exome array at the Center for Inherited Disease Research at Johns Hopkins 
University. 
3.2.3 Identification of Deletions 
Microdeletions were identified from SNP intensity data using the Bioconductor package 
“GWASTools”.  The deletions were detected from the “Log R Ration” (LRR), a measure of the 
relative signal intensity, and “B Allele Frequency” (BAF), an estimate for the B allele frequency 
of a SNP in the population of cells the DNA originated from.  GWASTools uses circular binary 
segmentation to identify change points in BAF and loss of heterozygosity by change in LRR.  In 
a region with normal copy number, we would expect to see a B allele frequency of 0 (AA), 0.5 
(AB) or 1 (BB) with an LRR of 0.  Heterozygous deletions were identified based on a loss of the 
intermediate BAF band and corresponding decrease in LRR.  For more information, please refer 
to the Quality Control Report issued by the University of Washington GCC here: 
(http://www.ccdg.pitt.edu/docs/Marazita_ofc_QC_report_feb2015.pdf) 
We restricted our analyses to large deletions (greater than 750 kb) found in OFC cases to 
enrich for likely pathogenic variants. LRR and BAF for each deletion were plotted for the case and 
both parents (if available).  Plots were manually inspected to determine if deletions were inherited 
or occurred de novo.  Poor quality deletions were removed as likely artifacts.  Out of our original 
sample of 2,989 individuals with OFCS, we detected 94 individuals with CL, CP, or CLP with 
such deletions.   
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3.2.4 Annotation 
Demographic and medical history data, pedigrees, and photos and videos were reviewed 
for each individual.  Patient presentations and deletions were then cross-referenced with the 
literature to determine whether the deletion, or the region in which the deletion was located, had 
previously been described as OFC-associated.  Based on this, our data was organized into 4 groups: 
(1) individuals with a highly–penetrant orofacial cleft-associated deletion syndrome (e.g. 
DiGeorge syndrome or Smith Magenis syndrome), (2) individuals with a lower penetrant orofacial 
cleft microdeletion (e.g. 1p36 and 1q21 microdeletions), (3) individuals with a large deletion 
encompassing likely contributory genes (e.g. COL11A), and (4) individuals with a deletion of 
unknown significance (<1 Mb).  Only one individual had a causative non-syndromic OFC gene 
deleted (FGFR2) that had been previously published by Osoegawa et al., and was excluded from 
our sample.8 
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Figure 1. Methods Flowchart 
 
2,989 OFC cases and family members
Genotyping and identification of microdeletions
Removal of poor quality deletions, those smaller than 
750 kb, and those not found in OFC cases 
Plots inspected for inheritance
Relevent data (phenotype, family history, pedigree) 
retrieved from registry and recorded for corresponding 
individuals
Literature research to determine if phenotype recorded 
matches what is recorded for the deletion/region in the 
literature (syndromic vs. non-syndromic, location of 
candidate genes, etc.)
Highly penetrant 
deletion syndromes
Lower penetrant 
deletion syndromes
Deletion of Unknown 
Significance
(Deletions under 1Mb that do 
not coincide with a known 
OFC gene and its associated 
phenotype)
Deletions over 3 MB 
that do not fall within 
described  orofacial 
cleft microdeletion 
regions
Genes within deleted 
region are researched 
and if significant to 
orofacial clefts, are 
included in the table
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3.3 RESULTS 
We identified a number of deletions that varied by size, inheritance, phenotypic spectrum, 
rarity, and previous report in the literature.  Descriptions of our subgroups are below. 
 
Table 1. Highly Penetrant Deletion Syndromes 
DELETION Mb INHERITANCE PHENOTYPE FAMILY HISOTRY SYNDROME 
4p16.3-p16.2 4.6 unknown, not maternal BCL, bifid uvula, pulmonary stenosis, 
seizures, hypoplastic kidney, triangular 
face, micrognathia, down slanting 
palpebral fissures, hypertelorism, simple 
ears, intellectual disability, developmental 
and speech delay 
sister with speech and 
developmental delay, 
synophrys, upward 
slanting palpebral 
fissures 
Wolf-Hirschhorn 
syndrome88 
17p11.2 3.6 de novo CP, micrognathia, chronic ear infections, 
and mild to moderate intellectual 
disability 
father with bifid uvula; 
brother with 
convergent strabismus 
Smith Magenis 
syndrome89 
22q11.21 2.6 unknown, not maternal LCLP, speech delay, type 1 diabetes, 
protruding ears with bumps, macroglossia, 
and micrognathia 
NA DiGeorge 
syndrome85 
22q11.21 2.6 de novo SMCP, dysmorphic features, double 
hernias, malrotation of organs, difficulty 
swallowing, and large tongue 
mother with SMCP; 
brother with functional 
heart murmur, frontal 
bossing, 
prominent/protruding 
ears, single palmar 
creases 
DiGeorge 
syndrome85 
22q11.21 2.1 de novo RCLP NA DiGeorge 
syndrome85 
22q11.21 2.6 de novo LCLP NA DiGeorge 
syndrome85 
22q11.21 1.4 unknown, not maternal CP maternal 5th degree 
relative with CP 
DiGeorge 
syndrome85 
22q11.21 2.4 de novo BCLP NA DiGeorge 
syndrome85 
22q11.21 2.6 unknown LCLP NA DiGeorge 
syndrome85 
22q11.21 2.8 unknown, not maternal CP NA DiGeorge 
syndrome85 
22q11.21 2.6 unknown, not maternal SMCP, chronic ear infections, VSD, 
hoarseness, loss of voice 
NA DiGeorge 
syndrome85 
22q11.21-
q11.23 
2.2 de novo BCLP NA DiGeorge 
syndrome85 
22q11.22-
q11.23 
2.0 de novo CLP NA DiGeorge 
syndrome85 
22q11.21-
q11.22 
2.9 de novo SMCP, speech delay, learning disability, 
fine motor skill delay, ADHD, anxiety, and 
hearing loss in left ear 
father with speech 
delay; mother with 
SMCP, speech delay, 
nerodermatitis; brother 
with speech delay 
DiGeorge 
syndrome85 
whole X 100 unknown CP NA Turner syndrome55 
whole X 90 unknown BCLP NA Turner syndrome55 
 
CL – cleft lip; RCL – right cleft lip; LCL – left cleft lip; BCL – bilateral cleft lip; CP – cleft palate; RCP – right cleft palate; LCP – left cleft palate; 
SMCP – submucosal cleft palate; CLP – cleft lip and palate; LCLP – left cleft lip and palate; RCLP – right cleft lip and palate; BCLP – bilateral 
cleft lip and palate; ADHD – attention deficit hyperactive disorder; VSD- ventricular septal defect 
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3.3.1 Highly Penetrant Deletion Syndromes 
As shown in Table 1, 22q11.2 deletions, the most common cause of cleft palate syndromes, 
make up more than 75% of our highly penetrant deletions group.  These deletions were on average 
around the standard 3Mb and encompassed the regions typical of DiGeorge syndrome.  Most were 
de novo, and if not listed as such, were described as having “unknown inheritance” because a DNA 
sample was unavailable from one or both parents.  Some of our registry data entries were more 
descriptive than others, including characteristic DiGeorge features such as developmental and 
speech delay, dysmorphic facial features, hoarse voice, and ventricular septal defect.  Others were 
sparse in information outside of clefting type.  Two individuals within this subgroup were found 
to have monosomy X, or Turner syndrome, but had no phenotypic information detailed other than 
cleft type. 
Wolf-Hirschhorn syndrome and Smith Magenis syndrome were represented in our cohort 
with one individual respectively.  Both patients presented with typical characteristics of their 
respective conditions, such as intellectual disability, dysmorphic facies, and seizures.  The 
individual with Smith Magenis syndrome had a 3 Mb de novo 17p11.2 deletion.  DNA was 
unavailable from the father of the patient with Wolf-Hirschhorn syndrome, so we could not 
determine if the deletion was inherited or de novo.  Interestingly, the proband’s sister also had 
delays and dysmorphic facies (although much milder than our patient), but no deletion was 
detected. 
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Table 2. Lower Penetrant Deletion Syndromes 
DELETION Mb INHERITANCE PHENOTYPE FAMILY HISTORY POSSIBLE 
SYNDROME 
RELEVANT 
GENES 
1p36.21 2.6 de novo RCL NA 1p36 microdeletion 
syndrome 
PDPN - 
usually results 
in heart 
defects, not 
CL/P98 
1p36.33-p36.23 6.9 de novo BCLP, seizures, 
hearing loss, 
hypotonia, 
hydronephrosis 
NA 1p36 microdeletion 
syndrome 
SKI; 
PRMD16 
cleft in mice98 
1q21.1-q21.2 1.5 maternal BCLP, learning and 
speech delays, 
clogged tear ducts, 
kidney reflux, 
hypertelorism, 
smooth philtrum 
maternal half-brother 
with supernumerary 
teeth, fetal pads, 
kidney reflux, 
learning disability in 
reading, 
tracheomalacia, ADD 
1q21.1 microdeletion 
syndrome 
GJA5, GJA8, 
CDH1L, 
GPR89B, 
NBFL11, 
BCL9 - 
usually low 
penetrance99,10
0 
1q21.1-q21.2 1.5 paternal BCLP paternal uncle with 
seizures 
1q21.1 microdeletion 
syndrome 
GJA5, GJA8, 
CDH1L, 
GPR89B, 
NBFL12, 
BCL9 - 
usually low 
penetrance99,10
0 
3p26.3 .86 paternal BCLP paternal aunt with 
intellectual disability; 
paternal aunt with 
absent fingers; brother 
with polydactyly 
CNTN6 deletion CNTN6101 
3q29 1.6 paternal BCLP brother with LCLP 3q29 microdeletion 
syndrome 
DLG1, 
PAK2102 
3q29 .92 maternal BCL, leukemia sister with 
hypertelorism, 
nystagmus, 
hypermobile joints, 
single palmar; 
paternal half-brother 
with severe acne, 
frontal bossing, right 
epicanthal folds, 
bilateral ptosis, 
anteverted nares, 
tapering fingers 
3q29 microdeletion 
syndrome 
DLG1102 
3q29 1.9 de novo RCLP NA 3q29 microdeletion 
syndrome 
DLG1, 
PAK2102 
3q29 1.7 de novo RCLP and was born at 
37 weeks and weighed 
4 lbs. 8 oz. 
NA 3q29 microdeletion 
syndrome 
DLG1, 
PAK2102 
6p25.3-p24.3 9.1 de novo RCLP, hypertelorism, 
Dandy Walker 
malformation 
NA 6p25 deletion 
syndrome 
FOXC1, 
F13A1, 
BMP1, 
DSP103104,105 
6p25.1-p24.3 2.9 maternal LCLP sister with BCLP, 
mother (LCL) and 
aunt (BCLP) with 
microdeletion  
6p25 deletion 
syndrome 
BMP1, 
DSP103104,105 
7q36.3 5.9 Unknown CLP NA 7q36 deletion 
syndrome 
SHH106 
7q36.3 2.7 de novo RCL, autism, 
strabismus, slanting 
palpebral fissures, 
NA 7q36.3 deletion 
syndrome 
LMBR1107108 
 23 
epicanthal folds, 
missing nasal bone 
and cartilage 
12q14.3-q21.1 7.1 unknown BCLP, bifid uvula, 
0.1 percentile for 
weight and BMI, 20th 
percentile for height, 
small facial features 
NA 12q14 microdeletion 
syndrome 
GRIP1, 
HMGA2 
12q21.1 2.1 de novo SMCP, pyloric 
stenosis, low set ears, 
dysmorphic facies, 
curly hair, speech 
delays 
sister with LCLP Cardiofaciocutaneous-
like syndrome109110111 
TRHDE and 
ATXN7L3B 
14q32.32-
q32.33 
4.3 de novo LCLP, right inguinal 
hernia, developmental 
delay, hearing 
impairment 
NA 14q32  JAG2112, 
XRCC3, 
ZFYVE21113 
15q11.2 .85 paternal BCLP, speech delays 2nd cousin with 
speech delay, LCLP; 
2nd cousin with 
learning disability 
15q11.2 microdeletion 
syndrome 
NIPA1, 
NIPA2, 
CYFIP1114 
15q14 3.5 maternal BCLP maternal aunt with 
deletion and LCLP 
15q14 deletion 
syndrome 
does not 
include 
candidate 
cleft gene 
MEIS2115 
 
CL – cleft lip; RCL – right cleft lip; LCL – left cleft lip; BCL – bilateral cleft lip; CP – cleft palate; RCP – right cleft palate; LCP – left cleft palate; 
SMCP – submucosal cleft palate; CLP – cleft lip and palate; LCLP – left cleft lip and palate; RCLP – right cleft lip and palate; BCLP – bilateral 
cleft lip and palate; ADD – attention deficit disorder 
 
3.3.2 Lower Penetrant Deletion Syndromes 
18 microdeletions were placed into our lower penetrant deletion syndrome subgroup as 
shown in Table 2. These are deletions that are found in the region of known deletion syndromes, 
but are often smaller than those described in the literature. Moreover, our sample clearly showed 
a range of penetrance and severity.  For example, we identified two deletions each on 1q21 and 
1p36; in both cases, one individual presented with only an OFC while the other had a syndromic 
presentation, showing symptoms such as seizures, hearing loss, and global delays. In the case of 
1p36, the syndromic features were present in the individual with a large 6.9Mb deletion. The 
apparently isolated OFC individual had a much smaller 2.6Mb deletion. 
Table 2 Continued 
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Some deletions had less of a recorded phenotypic impact than predicted based on the 
literature.  An almost 6 Mb 7q36.3 deletion, which included the SHH gene, had no recorded effects 
other than CLP, however photographs were unavailable to assess minor features of 
holoprosencephaly. Other phenotypes more clearly matched their genotypes; for example, an 
individual with a de novo 6p25 microdeletion had Dandy Walker malformation along with RCLP, 
consistent with the brain anomalies often seen with the syndrome.116  Similarly, a large 14q32 
terminal deletion patient had OFC (LCLP), developmental delay, and inguinal hernia which are 
often seen in terminal 14q32 microdeletion syndrome.1123 
The most represented deleted region in this subgroup was 3q29, with four individuals 
carrying a deletion.  The deletions averaged 1.5 Mb, the typical size of the deletion and in the same 
critical region.  Unlike what has been described in the literature (affected individuals with delays, 
kidney anomalies, microcephaly, and skin conditions), few features other than OFCs were 
recorded.  Two individuals with inherited microdeletions, one with a small 15q11.2 deletion and 
another with a large 14q14 deletion, also had limited phenotypic descriptions other than OFC, and 
few affected relatives.  This seemed to be consistent with the literature: 15q11.2 deletions are 
commonly cited as low penetrance, and the 15q114 deletion did not have many of the causative 
genes typically seen within the syndrome, such as MEIS2.  
Interestingly, we saw a family with a mid-sized 2.9Mb 6p25 microdeletion showing clear 
autosomal dominant inheritance and penetrance: an affected individual with LCLP had an affected 
mother with LCL and maternal aunt with BCLP, both who had the recorded deletion.  Although 
the region did not contain some of the genes more commonly encompassed within 6p25 
microdeletion syndrome, such as FOXC1, it seems possible that the deletion may be causative of 
the OFC phenotype within the family. 
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3.3.3 Rare Syndromic Deletions of Interest 
Within our “Lower penetrant deletion syndromes” subgroup, four individuals stood out: 
one with a 3p26.3 deletion with a family history of polydactyly, a patient with a 12q14.3-q21.1 
deletion and 12q14 deletion syndrome phenotype, another individual on the holoprosencephaly 
spectrum with a 7q36.3 deletion not including SHH, and one with a 12q21.1 deletion and a 
cardiofaciocutaneous syndrome-like phenotype. 
 
Table 3. Large Deletions 
DELETION Mb INHERITANCE PHENOTYPE FAMILY HISTORY RELEVANT 
GENES 
1p21.1-p13.3 4.1 de novo LCLP brother with LCLP COL11A11772 
1q31.1-q31.3; 
1p31.3; 1p22.3; 
1p22.1 
7.6 unknown LCLP NA LHX875118 
4p15.1-p14 6.3 unknown BCLP NA NA 
4q35.2 3.1 Paternal LCLP NA FRG1119 
10p13-p12.31 3.9 unknown, not 
maternal 
RCLP, intellectual disability, 
developmental delay, ADD 
brother with developmental delay, 
learning disability 
NA 
11p15.1-p14.3 3.7 maternal BCLP NA NA 
12q14-q15 4.8 de novo  CLP NA GRIP1120 
18q22.1-q23 14 de novo LCL maternal aunt with LCL TXNL4A121 
20p12.3-p12.1 7.7 de novo CP NA BMP2122, 
JAG1123 
 
CL – cleft lip; RCL – right cleft lip; LCL – left cleft lip; BCL – bilateral cleft lip; CP – cleft palate; RCP – right cleft palate; LCP – left cleft palate; 
SMCP – submucosal cleft palate; CLP – cleft lip and palate; LCLP – left cleft lip and palate; RCLP – right cleft lip and palate; BCLP – bilateral 
cleft lip and palate; ADD – attention deficit disorder 
3.3.4 Large Deletions 
 Table 3 included microdeletions larger than 3 Mb that did not fall into our high or low 
penetrant deletion syndrome categories because there were no associated syndromes. However, 
given their size, they may contribute to the pathogenesis of OFCs. We reviewed each deletion for 
potentially causative genes and the following were found: COL11A1, LHX8, FRG1, GRIP1, 
TXNL4A, BMP2, and JAG1.  Other deletions, including a paternally inherited 6.3 Mb 4p14.1-p14 
deletion, a maternally inherited 3.7 MB 11p15.1-p14.3 deletion, and a 3.9 Mb 10p14-p12.31 
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deletion, had no genes within the deleted regions that were suspected to be causative and could be 
considered variants of unknown significance. 
3.3.5 Deletions of Unknown Significance 
Table IV (Appendix A) includes deletions that do not have clear connections to OFC 
syndromes or OFC-associated genes.  In our cohort, 54% of the deletions fall into this category. 
These deletions should be further inspected in other OFC cohorts and in controls to determine if 
they may be associated with OFCs. The genes within them should also be considered for 
expression analyses or animal model studies. 
3.4 DISCUSSION 
The goal of this study was to describe the deletions and characteristics of an international 
orofacial clefting cohort with microdeletions.  We found that in our 94-patient sample, most of the 
microdeletions within our cohort were associated with a syndromic presentation, particularly 
DiGeorge syndrome.  Based on the empirical literate, we expect that these deletions are causal 
alone.  A large subset was also composed of lower penetrance microdeletions, such as individuals 
with 3q29 microdeletion syndrome.  These deletions are most likely contributing to the 
multifactorial inheritance of OFCs, and together with environmental and other genetic factors, 
produced an OFC phenotype.  Nine individuals had substantially sized deletions, most containing 
OFC-contributing genes such as JAG1 and COL11A. Fifty-one deletions were of uncertain 
significance, or came with limited phenotypic data.  Interestingly, only one non-syndromic OFC-
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associated deleted region was found within our sample, despite non-syndromic OFCs traditionally 
being cited as more common than syndromic OFCs.2  Finally, four deletions of interest were noted 
in our sample, and their potential significance along with suggestions for future review are 
described in the following section: 
3.4.1 3p26.3 
3p26 deletions, particularly terminal 3p26.1 deletions, have been associated with a wide 
variety of symptoms, including developmental delay, intellectual disability, polydactyly, renal 
anomalies, heart defects, ptosis, and sacral dimples.124125  Although some research has suggested 
that smaller 3p deletions, such as 3p26.3 deletions which encompass the CNTN6 gene, may cause 
developmental delay, learning disabilities, or milder intellectual disability, the broader range of 
symptoms seen with larger deletions has not been recorded.101  An individual with a paternally 
inherited 0.9 Mb 3p26.3 microdeletion has a bilateral cleft palate, along with a brother with 
polydactyly and a paternal aunt with intellectual disability.  Although these phenotypic findings 
may be associated with other genetic or environmental factors, they may also be suggestive of 
3p26.3 and CNTN6 microdeletions having a larger range of associated phenotypes than previously 
suggested.  Genetic testing of the possibly affected family members would be helpful in 
determining the significance of the deletion. 
3.4.2 7q36.3 
 The SHH gene is well known for playing a role in embryonic development, taking part in 
craniofacial, limb, and spinal cord organization and growth, with a particular influence on the 
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midline of the body.126  The cis-regulators that help moderate SHH are located within SHH, in the 
gene desert adjacent to SHH, and the genes following it, including LMBR1, in which the ZRS 
regulator falls.  Mutations within LMBR1 can affect ZRS, which impacts the development of the 
limbs, causing symptoms such as post-axial polydactyly.107,108   Our cohort contains an individual 
with a 7q36.3 deletion that does not include SHH, but does include LMBR1.  Although our 
individual does not have any recorded limb abnormalities, they do have an absent nasal bone and 
cartilage, a phenotype seen in individuals with midline defects tied to the SHH gene.  This opens 
the possibility of the presence of other regulatory factors, perhaps within LMBR1, that can affect 
SHH and its role in the development of the midline. 
3.4.3 12q14.3-q21.1 
12q14 microdeletion syndrome, a condition often compared to Russel-Silver syndrome,  
encompasses a spectrum of characteristics including dwarfism, slow growth, small facial features, 
developmental delay, and osteopoikilosis (dense, hyperstatic areas of the bone).127 In the literature, 
loss of the gene HMGA2 within this region is thought to be the cause of the growth problems seen 
within the disorder.  We identified one deletion of 12q14 that included HMGA2 with concomitant 
features, such as being in the 0.1 percentile for BMI and 20th percentile for height, and having 
small facial features. A second, smaller deletion did not include HMGA2, leading to the possibility 
that another gene may be contributing to the clefting phenotype shared between these individuals. 
Both deletions included GRIP1, a gene also associated with 12q14 microdeletion syndrome, but 
not tied directly to problems of size and growth.128   
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3.4.4 12q21.1 
Cardiofaciocutaneous syndrome (CFC) is a genetic syndrome with features including heart 
defects, dysmorphic facial features, skin and hair abnormalities, and intellectual disability.129  Most 
commonly, mutations are found in the BRAF gene on chromosome 7.  However, in recent years, 
multiple case reports have been published describing individuals with a CFC-like phenotype and 
12q21 deletions, despite some controversy concerning the fit of the diagnosis.130  The three patients 
described have some shared features with CFC including ptosis, low set ears, micrognathia, sparse, 
coarse hair, cardiac defects, developmental delay, generalized follicular hyperkeratotic papular 
eruption, and pyloric stenosis.109–111  Within our cohort, we have also found an individual with a 2 
MB de novo 12q21.1 deletion presenting with submucosal cleft palate, pyloric stenosis, speech 
delays, low set ears, curly hair, dysmorphic facies, and a rash on the skin like that seen in children 
with generalized follicular hyperkeratotic papular eruption (Figure 2).  These phenotypic findings 
may represent a candidate gene location for CFC or new condition with similar symptoms. 
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Figure 2. Patient with 12q21 Deletion and CFC-like Features 
 
A limitation of our study was that the data was collected in a research setting, and not a 
clinical one.  Patients were assessed by people without medical training, and not by clinical 
geneticists with expertise in dysmorphology; photographs were only taken sporadically. Most of 
the subjects were recruited as part of the Pittsburgh Orofacial Cleft Study (POFC), focused on 
identifying subclinical phenotypes of OFCs. The protocols for this study are extensive compared 
to other recruitment strategies, but still rely on self-reported demographic and medical histories. 
POFC involved multiple international recruitment sites, each with variations in the amount of 
phenotypic data recorded.  When available, the 3D photographs and videos were useful in 
identifying dysmorphic features, however not all relevant features are visible in photographs or 
known to the families. This is especially true when the children were recruited during infancy or 
as toddlers, who may not have had prominent dysmorphic facies or who had not yet failed to meet 
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developmental milestones. Even for a well-described microdeletion syndrome like DiGeorge 
syndrome, a heart defect may have previously gone undetected, due to a lack of prior concern for 
a chromosomal disorder. 
Another consideration is that the standard of care continues to change. At present, infants 
with multiple congenital anomalies typically receive a clinical microarray to identify or rule out 
microdeletion syndromes; others receive mutation screening or clinical whole exome sequencing. 
The POFC sample was recruited over the last twenty years, prior to widespread use of clinical 
microarrays. In addition, many of the subjects were recruited from international sites, including on 
cleft repair missions to the Philippines and Guatemala, where diagnosing syndromes is not the 
highest priority. It is also important to note that diagnosis of syndromes is often easier after the 
identification of the deletion, as was the case in this study.   
3.5 CONCLUSION 
The international data we have collected and analyzed adds to the literature of deletions 
associated with OFCs.  Unlike previous research that examined microdeletions in OFCs, our data 
showed almost no deletions in previously described non-syndromic regions.8,80,131  Most of our 
deletions were within described syndromic regions previously associated with OFCs, with many 
that have a wide variety of other associated symptoms. These additional deletions will be helpful 
in delineating critical regions for craniofacial and OFC phenotypes. Our cohort, by showing the 
range of body systems affected by these deletions, help to demonstrate that careful monitoring 
along with proactive care are important for clinical management when one of the deletions is 
detected.  Finally, the syndromic deletions of interest that we have noted could also open avenues 
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of new and further research into their significance, and could potentially enter the clinical realm 
in the future. 
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4.0  RESEARCH SIGNFICANCE TO GENETIC COUNSELING AND PUBLIC 
HEALTH 
Orofacial clefts (OFCs) pose a significant public health burden.  OFCs are common 
malformations, occurring in 1 in every 700 births worldwide.  The health care cost of these 
malformations has been well documented; the average cost over the lifetime for cleft lip and palate 
(CLP) treatment is over $200,000.   Monetary consequences are not the only ones that exist; OFCs 
can cause a range of health concerns including dental, feeding, hearing, speech, and mental health 
problems.2  Because of this, research to determine the etiology of OFCs has been extensive to help 
identify possible targets for treatment development to relieve the economic and medical burden 
that present with OFCs.  Although the literature on the genetics of OFCs is extensive, only 25% 
of the heredity of non-syndromic OFCs has been explained, with 75% still unexplained. 
The present study looks at only one kind of causative genetic abnormality, microdeletions.  
Despite this narrow scope, the information gleaned from our research adds to the growing literature 
of the genetics of OFCs.  The data also contributes meaningful information when considering the 
public health significance of these malformations.  In terms of the first core function of public 
health, assessment, our research has successfully “collect(ed) and analyz(ed) information about 
health problems.”  Within our cohort, we have identified and described new microdeletion 
syndromes, particularly in the case of the individual with a de novo 12q21.1 deletion and a 
cardiofaciocutaneous-like presentation.  Additionally, in terms of previously described 
microdeletions, we have found several features that have extended our understanding about 
potential phenotypes, such as the individual with 12q14 deletion syndrome who had bilateral cleft 
lip and palate, which has not been described in the literature.  With the recognition of these rare 
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syndromes, we have collected information to provide to medical professionals, including genetic 
counselors that will aid in the diagnosis and management of individuals with OFCs.  As more is 
studied and understood, we can give this information to families to provide accurate descriptions 
of phenotypic presentations, disease course, and recurrence risk, along with using it for shaping 
management and surveillance standards. 
Another essential public health core function that our research addresses is assurance, 
particularly in terms of “assur(ing) a competent public health and personal healthcare workforce.”  
As mentioned previously, many of the individuals in our cohort would benefit from surveillance 
to determine whether other previously recorded characteristics are present.  However, many of the 
individuals within our cohort were not recognized as having a syndromic presentation prior to 
genetic testing, despite a wide range of other symptoms being listed.  These missed diagnoses may 
be indicative of a lack of proper genetics education among national and international medical 
professionals.  Additionally, microarray, a genetic test used to detect microdeletions, is a front-
line test now offered to individuals with a congenital anomaly.1  Many of these individuals, 
particularly with common microdeletions such as 22q11.2, the causative deletion for DiGeorge 
syndrome, could have been diagnosed much earlier if they had been given this testing upon 
detection of an OFC and other symptoms.  This is particularly relevant because other internal 
anomalies associated with the condition could be recognized and treated early, such as heart 
defects, and supports like early intervention services could be offered to individuals at risk for 
developmental delay.  Again, our research illustrates the differences in standards of care and the 
importance of educating clinicians on the relevance of genetic testing for their patients.  Genetic 
counselors are uniquely qualified for this type of role, and perhaps in the future could develop 
educational programs and/or resources targeted in areas known for having a lower genetic literacy. 
 35 
This research provides information that could impact genetic counseling practice.  The 
etiology of CL, CP, and CLP is complex; as described previously, environmental multifactorial, 
and Mendelian causes all exist.  This can make genetic counseling for orofacial clefts challenging.  
Typically, recurrence risks are cited as 3-5% when a previous child or other close relative has non-
syndromic CL/P (the typical recurrence risk quoted for most congenital anomalies).  This is based 
on the thought that most non-syndromic OFCs are due to multifactorial inheritance.69  Although 
the discovery of new genetic regions tied to OFC help elucidate possible causes, it remains unclear 
about how much (or little) they contribute to the phenotype.  Deletions within the 1q21 region, for 
example, though associated with a wide array of symptoms including OFC, have a low penetrance, 
and characteristics in individuals with the deletion can vary significantly even within a family.100  
Because of this level of uncertainty, more research will need to be conducted on non-syndromic 
OFC related regions to better counsel patients on risk.  Once this is done, we will be able to quantify 
and quote more accurate risk values to patients and their families.  This study has outlined many 
low penetrance deletions, their inheritance patterns, and phenotypic characteristics.  The 
information we found can be used clinically to help inform patients of the spectrum their child 
may fall along.  As similar studies are performed in the future and more data on these specific 
deletions are collected, we may be able to better determine the significance of the deletions and 
how they interact with the genome and the environment.  
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APPENDIX A: SUPPLEMENTARY TABLE 
Table 4. Deletions of Unknown Significance 
DELETION Mb INHERITANCE PHENOTYPE FAMILY HISTORY 
1p22.1 1.0 de novo SMCP NA 
1p22.1 1.0 de novo LCLP father with LCLP 
1p22.1 1.4 de novo RCLP NA 
1p22.1 .84 both 
(homozygosity) 
LCL, minor epicanthal folds NA 
1p22.1 .89 unknown CLP brother with LCL; brother with 
bifid uvula 
1p22.1 .89 unknown, not 
maternal 
microform LCL NA 
1p35.3 .88 unknown, not 
paternal 
BCLP brother with LCLP; brother with 
CLP; brother with RCL; paternal 
half-brother with CLP 
2p25.3 1.5 paternal RCLP NA 
2q11.2 1.4 unknown LCL NA 
2q12.3 1.3 unknown LCLP mother with SCP, bifid uvula 
2q14.2 1.2 maternal CP NA 
2q33.2-q33.3 1.1 de novo RCLP father with CP; first cousin once 
removed with RCLP 
2q33.2-q33.3 .77 unknown LCLP father with LCLP 
2q33.2-q33.3 .77 unknown BCLP NA 
2q33.2-q33.3 .77 maternal CLP, heart murmur mother with learning disability; 
sister with heart murmur 
3q26.1 1.4 de novo RCLP, chronic ear infections, blocked left tear 
duct 
maternal grandmother with 
intellectual disability, paternal 
grandmother with extra adult 
teeth, father with heart murmur, 
mother with bipolar disorder 
3q28 1.9 unknown, not 
maternal 
RCLP great nephew with speech and 
developmental delay 
4q35.2 .95 maternal BCLP NA 
5q13.1-q13.2 1.6 unknown BCLP NA 
5q21.2 .90 maternal RCLP NA 
6p22.1 1.3 paternal incomplete LCL NA 
6q22.32-q22.33 .94 unknown BCLP NA 
7p22.1 1.9 unknown, not 
maternal 
BCLP 5th degree paternal relative with 
RCLP 
7p22.3-p22.1 2.9 de novo LCL NA 
7q11.23 1.4 unknown, not 
maternal 
LCLP NA 
8q23.2-q23.3 3.8 unknown, not 
maternal 
RCL NA 
10q25.3-q26.11 .78 unknown, not 
from mother 
incomplete RCL maternal grandmother LCLP 
10q25.3-q26.11 .79 unknown LCL NA 
10q25.3-q26.15 .79 unknown, not 
maternal 
BCLP, speech and behavioral disorder, low set 
ears 
NA 
11p11.12-p11.1 1.0 paternal BCLP NA 
11p15.4 1.1 unknown RCL brother with CL; sister with CL; 
father with CLP; first maternal 
cousin with LCLP 
13q12.12-q12.3 1.4 unknown BCLP NA 
13q31.3 .79 maternal CP brother with CL 
13q33.2-q34 8.9 unknown, not 
maternal 
BCLP NA 
14q11.2 .94 unknown RCLP NA 
14q12 .90 unknown BCLP NA 
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15q11.1-q11.2 3.1 maternal LCL NA 
15q11.2 .77 maternal LCLP NA 
15q11.2 .85 paternal RCLP NA 
15q13.3 .87 paternal LCLP, speech delays, learning disability, small father with hemihypertrophy 
15q13.3-q14 1.9 maternal BCLP NA 
15q14 .90 unknown BCLP and speech delays father with behavioral problems, 
learning disability, undescended 
left testicle 
17p12 1.3 de novo LCL NA 
17q11.2 1.2 de novo BCLP and bifid uvula NA 
17q21.33 1.6 unknown BCLP, speech delay brother with CL, and 4th degree 
paternal relative with CL 
17q22-q23.2 2.0 de novo BCLP NA 
17q25.3 .77 maternal BCLP maternal half-brother with CL; 
maternal half-brother with CLP; 
maternal 5th degree relative with 
CP; maternal 5th degree relative 
with CL 
18q11.2-q12.1 1.3 paternal LCLP NA 
19q13.12 .85 unknown, not 
from mother 
SMCP, bifid uvula, learning disability, 
difficulty running, hearing loss 
father with CP; twin sister with 
bifid uvula 
19q13.12-q13.2 .98 de novo CP, speech delay, behavioral problems, learning 
disability, failure to thrive, heart murmur, ODD 
and ADHD 
4th and 5th degree maternal 
relatives with CP 
 
CL – cleft lip; RCL – right cleft lip; LCL – left cleft lip; BCL – bilateral cleft lip; CP – cleft palate; RCP – right cleft palate; LCP – left cleft palate; 
SMCP – submucosal cleft palate; CLP – cleft lip and palate; LCLP – left cleft lip and palate; RCLP – right cleft lip and palate; BCLP – bilateral 
cleft lip and palate 
 
Table 4 Continued 
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